Abstract
About half of patients with metastatic breast cancer (mBC) have unresectable liver metastases (LMs) or liver-predominant disease (LPD). Unfortunately systemic chemotherapy has limited tumor response due to LMs are supplied by hepatic artery. Hepatic intra-arterial (HAI) have antitumor activity in pretreated patients with LMs. Here we report the case of a 55-year-old woman affected by BCLPD and heavily pretreated. LMs responded to treatment based on HAI with 5-fluorouracil and nabpaclitaxel systemic chemotherapy, and they completely disappeared on a CT-scan. We conclude that this combination chemotherapy is safe and may be very useful for the treatment of patients with BCLPD. Therefore, this combination should be evaluated in a large study.
Author supplied keywords
Cite
CITATION STYLE
Ranieri, G., Marech, I., Porcelli, M., Giotta, F., Palmiotti, G., Laricchia, G., … Gadaleta, C. D. (2018). Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel. Oncotarget, 9(8), 8197–8203. https://doi.org/10.18632/oncotarget.23793
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.